Corrections to Note

Get Permission

Robert Coleman, MD

In the January 15, 2014, issue of The ASCO Post, three errors occurred. These errors have since been corrected and revised versions of the articles may be viewed online at or via the QR code here. The errors were as follows below.

Trastuzumab Dosing

In the article “HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen,” dosing information provided for trastuzumab (Herceptin) in regard to a more tolerable regimen was incorrectly reported on page 33. The sentence should have read as follows below; revised text is underlined: “Patients received only paclitaxel at 80 mg/m2 weekly plus trastuzumab weekly at 2 mg/kg for 12 weeks, followed by 9 months of trastuzumab ­every 3 weeks at 6 mg/kg alone.”

Mistaken Identity

In the article “Adjuvant Bisphosphonates in Early Breast Cancer: Practice-Changing Findings?” there was an incorrectly identified photograph of the lead study author, breast cancer expert Robert Coleman, MD, of the University of Sheffield, United Kingdom. The published photo was actually one of Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center. A photograph of Dr. Coleman, the study author from the United Kingdom, is shown here.

Pioneers in Oncology

In the article “With the Goal of Curing Cancer, Ezra M. Greenspan, MD, Helped Usher in the Modern Era of Chemotherapy,” the final sentence of the article was incorrect. It should have read as follows: Dr. Ezra M. Greenspan and his wife, Ann, had three children—Karen, Ellen, and David.

The editorial staff regret these errors and apologize to the individuals mentioned in the respective stories as well as to readers of The ASCO Post.